跳至主要内容
临床试验/ACTRN12616000014459
ACTRN12616000014459终止未知

Investigating the neurobiological and neurocognitive effects of repeated sessions of tDCS and itDCS in schizophrenia.

Dr Kate Hoy0 个研究点目标入组 60 人开始时间: 2016年1月12日最近更新:
适应症

试验速览

阶段
未知
状态
终止
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 60 Years(—)
性别
All

入选标准

  • competent to consent based on their ability to provide a spontaneous narrative description of the key elements of the study, as assessed by a clinical staff member independent of the research project
  • -have a diagnosis of schizophrenia or schizoaffective disorder as confirmed by the MINI
  • -are between the ages of 18 and 60
  • - have been on a stable dose of medication for at least 4 weeks

排除标准

  • -have a DSM-IV history of substance abuse or dependence in the last 6 months
  • -have a concomitant major and unstable medical or neurological illness
  • -are pregnant
  • -are currently taking any medication shown to interfere with the effects of tDCS; namely benzodiazepines or tegretol.

研究者

发起方
Dr Kate Hoy

相似试验